Overview
Global Lupus Nephritis Treatment market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Lupus nephritis is a kind of kidney disorder induced by systemic lupus erythematosus. Lupus is an autoimmune condition a disease in which the body’s immune system attacks the body’s own cells and organs. Kidney disorders induced by lupus may get more threatening over the period and direct to kidney failure. The signs of lupus nephritis may enclose foamy urine and edema that transpires when the body has excessive fluid, frequently in the legs, feet, or ankles, and sometimes in the hands or face. The patient may even develop high blood pressure.
The primary purpose of managing lupus nephritis is to circumvent chronic kidney disease (CKD). Existing therapy approaches remain inadequate in representations of total renal response, precluding regressions, CKD, and advancement to end-stage kidney disorder. According to the Lupus Foundation of America, roughly 1.5 million individuals in the United States suffer from lupus, and up to 60% of them are estimated to develop lupus nephritis.
Market Dynamics: Drivers & Restraints
Increasing Product Approvals
The increasing drug product approvals to treat lupus nephritis is expected to boost the global market growth during the forecast period. For instance, in January 2021, Aurinia grasped its first FDA authorization for Lupkynis (voclosporin) for the treatment of lupus nephritis, or kidney inflammation induced by systemic lupus erythematosus.
Moreover, in February 2023, GSK plc obtained the US Food and Drug Administration (FDA) Orphan Drug Designation (ODD) to Benlysta (belimumab), a B-cell inhibiting monoclonal antibody, for the potential therapy of systemic sclerosis. Benlysta (belimumab) is a B-lymphocyte stimulator (BLyS) specific inhibitor that attaches to soluble BLyS, which is encountered to be raised in individuals with systemic autoimmune disorders like systemic lupus erythematosus (SLE) and lupus nephritis (LN).
Furthermore, the growing awareness about lupus nephritis, market developments, increase in research investments and activities are also driving the global market growth during the forecast period.
Stringent Regulatory Authorities
The stringent regulatory authorities authorizing the drug treatments are expected to hamper the global market growth. Furthermore, high drug development costs and treatment side effects are also expected to hamper the global market growth in the forecast period.

Segment Analysis
The global lupus nephritis treatment market is segmented based on treatment, route of administration, distribution channel and region.
Stem Cell Therapy Expected to Dominate Market
The increasing regulatory approvals for stem cell therapy are expected to boost the segment growth, dominating the global market in the forecast period. For instance, in June 2023, Kyverna Therapeutics ("Kyverna"), a cell therapy corporation with the mission of engineering a new class of therapies for severe autoimmune disorders, obtained the U.S. Food and Drug Administration (FDA) Fast Track designation for KYV-101 for the therapy of individuals with refractory lupus nephritis (LN). KYV-101 is a novel anti-CD19 chimeric antigen receptor T-cell (CAR T) therapy developed to deplete B cells, including autoreactive B cells, in autoimmune disorder patients
Moreover, in August 2023, Artiva Biotherapeutics, Inc., a clinical-stage corporation obtained the U.S. FDA Investigational New Drug (IND) designation for its AlloNK (also known as AB-101) a non-genetically-modified, cord blood-derived, allogeneic, cryopreserved NK cell therapy candidate, in mixture with rituximab for the treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis (LN).

Geographical Analysis
North America is Expected to Dominate the Global Market
Increasing clinical research activities in North America is expected to boost the regional market growth dominating the global market during the forecast period. For instance, in June 2023 Lupus Therapeutics formed a coalition to conduct three Phase 3 clinical trials testing an experimental therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis.
Lupus Therapeutics, the clinical investigation affiliate of the Lupus Research Alliance, intends to assist Novartis Pharmaceuticals Corporation (Novartis) in conducting the trials via the Lupus Clinical Investigators Network (LuCIN) at leading academic centers throughout North America.
Moreover, in March 2023 AbbVie reported topline outcomes from a Phase 2 study of upadacitinib (RINVOQ, 30 mg) delivered independently or as combination therapy (ABBV-599) with a Bruton’s Tyrosine Kinase inhibitor (elsubrutinib, 60 mg), once every day in patients with moderately to severely active systemic lupus erythematosus (SLE). AbbVie is extending its clinical schedule of upadacitinib in SLE to Phase 3.

COVID-19 Impact Analysis
During the COVID-19 pandemic, individuals with autoimmune rheumatic diseases (ARDs), including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, lupus, and vasculitis, had learned risk factors that raised their chance of infections, intricacies from infection, and mortality from COVID-19 owing to compromised immune systems linked to their condition or the medications often prescribed to treat these conditions.
Market Segmentation
By Treatment

  • Drug Treatment
    o Acamprosate
    o Pentoxifylline
    o Infliximab
    o Benzodiazepines
    o Corticosteroids
    o Others
  • Stem Cell Therapy
    By Route of Administration
  • Injectable
  • Oral
    By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
    By Region
  • North America
    o U.S.
    o Canada
    o Mexico
  • Europe
    o Germany
    o UK
    o France
    o Italy
    o Spain
    o Rest of Europe
  • South America
    o Brazil
    o Argentina
    o Rest of South America
  • Asia-Pacific
    o China
    o India
    o Japan
    o Australia
    o Rest of Asia-Pacific
  • Middle East and Africa
    Key Developments
  • In November 2022, Aurinia Pharmaceuticals Inc. obtained the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Great Britain marketing authorization for LUPKYNIS (Voclosporin) for the treatment of adults with active lupus nephritis (LN), a severe intricacy of systemic lupus erythematosus (SLE).
  • In August 2023, ImmPACT Bio USA, Inc., a clinical-stage corporation designing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies to treat cancer and autoimmune disorders, obtained the U.S. Food and Drug Administration (FDA) investigational new drug (IND) designation for IMPT-514, a bispecific CD19/CD20 CAR T therapy for the treatment of active, refractory systemic lupus erythematosus (SLE).
  • In August 2023, GRI Bio, Inc., a biotechnology corporation offering an inventive pipeline of Natural Killer T (“NKT”) cell modulators to treat inflammatory, fibrotic and autoimmune disorders, performed a presentation of preclinical data from its GRI-0803 development program at The Autoimmunity Conference hosted by FASEB held in July-August 2023 in Southbridge, MA.

    Competitive Landscape
    The major global players in the market include Aurinia Pharmaceuticals Inc., AstraZeneca, Novartis Ag, Beigene, Ltd., Glaxosmithkline Llc, Equillium, Inc., Kymera Therapeutics, Inc., Remegen Co., Ltd., And Immpact Bio Usa Inc. among others.
    Why Purchase the Report?
  • To visualize the global lupus nephritis treatment market segmentation based on treatment, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of lupus nephritis treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.
    The global lupus nephritis treatment market report would provide approximately 61 tables, 56 figures and 186 pages.
    Target Audience 2023
  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies